MET Positive

1 clinical trials · Condition

Record	Firm	Date
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches (NCT02926638)	SWOG Cancer Research Network	2014-06-16

Every clearance here is in the API, with alerts when new ones post.